These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 29701284)

  • 1. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
    Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
    ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
    Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure.
    Wang LY; Ghossein R; Palmer FL; Nixon IJ; Tuttle RM; Shaha AR; Shah JP; Patel SG; Ganly I
    Thyroid; 2015 Sep; 25(9):993-8. PubMed ID: 26122000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microscopic positive margins strongly predict reduced disease-free survival in pT4a papillary thyroid cancer.
    Abraham E; Roshan D; Tran B; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
    Head Neck; 2019 Aug; 41(8):2549-2554. PubMed ID: 30860642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does microscopically involved margin increase disease recurrence after curative surgery in papillary thyroid carcinoma?
    Lang BH; Shek TW; Wan KY
    J Surg Oncol; 2016 May; 113(6):635-9. PubMed ID: 26843438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
    Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
    Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
    Llamas-Olier AE; Cuéllar DI; Buitrago G
    Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors Associated With Recurrence and Death in Patients With Tall Cell Papillary Thyroid Cancer: A Single-Institution Cohort Study With Predictive Nomogram.
    Wu SS; Joshi N; Sharrett J; Rao S; Shah A; Scharpf J; Burkey B; Lamarre ED; Prendes B; Siperstein A; Shin J; Berber E; Jin J; Krishnamurthi V; Nasr C; Hong L; Buchberger DS; Woody N; Koyfman SA; Geiger JL
    JAMA Otolaryngol Head Neck Surg; 2023 Jan; 149(1):79-86. PubMed ID: 36454559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does microscopic positive tumor margin in papillary thyroid cancer really matter?
    Back K; Kim SK; Chai YJ; Kim JH; Choe JH; Kim JS
    Surgery; 2019 Dec; 166(6):1160-1167. PubMed ID: 31582308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of tumor size and focality with recurrence/persistence in papillary thyroid cancer patients treated with total thyroidectomy along with radioactive-iodine ablation and TSH suppression.
    Khan M; Syed AA; Khan AI; Hussain SR; Urooj N
    Updates Surg; 2018 Mar; 70(1):121-127. PubMed ID: 28550398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
    Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
    Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microscopic Positive Tumor Margin Does Not Increase the Risk of Recurrence in Patients with T1-T2 Well-Differentiated Thyroid Cancer.
    Kluijfhout WP; Pasternak JD; Kwon JS; Lim J; Shen WT; Gosnell JE; Khanafshar E; Duh QY; Suh I
    Ann Surg Oncol; 2016 May; 23(5):1446-51. PubMed ID: 26628431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of tumor size and minimal extrathyroidal extension in papillary thyroid carcinoma.
    Shin CH; Roh JL; Song DE; Cho KJ; Choi SH; Nam SY; Kim SY
    Am J Surg; 2020 Oct; 220(4):925-931. PubMed ID: 32081409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A UK based two-centre review of multifocality and its role in the treatment of papillary thyroid cancer.
    Li LQ; Hey SY; Andreeva D; Tornari C; Sawant R; Harding NE; Adamson R; Hay A; Simo R; Nixon IJ
    Eur J Surg Oncol; 2022 Jan; 48(1):14-20. PubMed ID: 34253424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.